SEC Form 4 · accession 0001589776-26-000004
FENNEC PHARMACEUTICALS INC. · FENC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marco Maria Brughera
Director
Period of report
Sep 15, 2026
Accepted (ET)
Sep 16, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001211583
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Sep 15, 2026 | M | 15,545 | $2.11 | A | 15,545 | D | |
| Common SharesF2 | Sep 15, 2026 | S | 15,545 | $10.29 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF3 | $2.11 | Sep 15, 2026 | M | 15,545 | D | Dec 30, 2016 | Dec 30, 2026 | Common shares | 15,545 | 220,000 | D |
Explanation of responses
- F1Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on June 16, 2026.
- F2Shares sold pursuant to a 10b5-1 plan adopted on June 16, 2026.
- F3Represents options exercised pursuant to a 10b5-1 plan adopted on June 16, 2026.